Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Multiple Myeloma × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Leukemia 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Stomach Neoplasms 1 Solid Tumors 1 Recurrence 1 Prostatic Neoplasms 1 Neurofibromatosis 1 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Advanced Solid Tumors 1

Interventions

Dexamethasone 301 Bortezomib 157 Lenalidomide 130 pomalidomide 107 daratumumab 92 carfilzomib 68 Calcium Dobesilate 41 Cyclophosphamide 40 elotuzumab 29 belantamab mafodotin 29 fludarabine 27 ixazomib 23 isatuximab 21 Melphalan 21 venetoclax 18 talquetamab 15 selinexor 15 Prednisone 15 plerixafor 14 Panobinostat 14 Granulocyte Colony-Stimulating Factor 14 idecabtagene vicleucel 11 Zoledronic Acid 11 Thalidomide 11 Injections 11 Azacitidine 11 pembrolizumab 10 nirogacestat 9 liposomal doxorubicin 9 iberdomide 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡